WO2004096200A1 - Kombination aus desoxypeganin und mecamylamin zur behandlung des alkoholmissbrauches - Google Patents
Kombination aus desoxypeganin und mecamylamin zur behandlung des alkoholmissbrauches Download PDFInfo
- Publication number
- WO2004096200A1 WO2004096200A1 PCT/EP2004/004033 EP2004004033W WO2004096200A1 WO 2004096200 A1 WO2004096200 A1 WO 2004096200A1 EP 2004004033 W EP2004004033 W EP 2004004033W WO 2004096200 A1 WO2004096200 A1 WO 2004096200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- mecamylamine
- ingredient combination
- pharmaceutically acceptable
- combination according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to pharmaceutical preparations which contain 3-deoxypeganine and / or ecamylamine.
- the invention further relates to the use of this combination of active substances for the therapy of harmful alcohol consumption and alcohol addiction,
- alcohol is the oldest, most widespread and by far the most important in terms of its health, social and economic effects.
- alcohol is the oldest, most widespread and by far the most important in terms of its health, social and economic effects.
- Germany there are around 1.6 million clinically dependent on alcohol and 2.7 million people with medically harmful alcohol consumption.
- naltrexone and gamma-hydroxybutyrate produce significant gastrointestinal and psychomotor side effects that impair compliance with the therapy.
- Naltrexone is also characterized by low oral bioavailability (approx. 5% of the amount taken is effective) moreover hepatotoxic, while gamma-hydroxybutyrate itself has addictive potential.
- cholinergic neurotransmission which include cholinesterase inhibitors in particular, occupy a special position in alcoholism therapy that has received little attention.
- cholinergic drugs can improve cognition that is impaired by alcohol-related damage to the cholinergic conduction pathways, thereby increasing insight into the problem.
- cholinergic therapies can also bring about an immediate, non-cognitive reduction in the desire for alcohol. According to the current state of knowledge, this is mediated by the neuronal nicotinic acetylcholine receptors (nAChR), which are located not only on cholinergic but also on dopaminergic neurons in the mesolimbic system.
- nAChR neuronal nicotinic acetylcholine receptors
- Deoxypeganine (1,2,3, 9-tetrahydropyrrollo [2, 1-b] quinazoline) is a cholinesterase inhibitor that does not bind to nAChR in pharmacologically relevant concentrations and additionally inhibits monooxidase A (but not monoamine oxidase B). This substance is also extremely suitable for the therapy of alcohol abuse, as described in DE 199 06 974 and the documents WO 00/48600 and EP 1 154 776 derived therefrom.
- mecamylamine administered two hours before drinking alcoholic beverages, reduced the central stimulating psychotropic effects and presumably also the pharmacokinetics of alcohol. Neither of these three works mentions the combination and / or simultaneous administration of mecamylamine with other pharmacologically active substances, in particular not with cholinesterase inhibitors or nicotinic agonists.
- the rat strain "AA”, bred in Finland, has a genetically determined preference for alcohol, ie the animals prefer alcohol-free liquids to alcohol-free liquids to satisfy their fluid needs, even without pretreatment with alcohol. This strain has therefore been used in numerous studies on the pharmacology of alcohol and is characterized excellently.
- Deoxypeganine hydrochloride (hereinafter referred to as "DOP") was obtained from the Institute of Plant Pharmacology (Tashkent, Uzbekistan) and provided by LTS Lohmann Therapie-Systeme (Andernach, Germany) after checking its identity and purity. Mecamylamine was considered to be commercial preparation obtained from Sig a-Aldrich GmbH (Munich).
- Mecamylamine was dissolved in 0.9% saline and administered in a volume of 5 ml / kg body weight by intraperitoneal injection.
- DOP was applied as an aqueous solution in a volume of 10 ml / kg using a pharyngeal tube. In the case of combination treatments, these administrations were carried out within a period of less than 10 minutes. At least two treatment-free days were always interposed before and after the treatment days.
- the target parameters were monitored during the 12 hours of the dark period following the treatment, with intermediate results after the first 4 hours and final results after 12 hours.
- the statistical Evaluation of the test data was carried out with the t-test for dependent values.
- the results with regard to alcohol consumption and alcohol preference are summarized in Figures 1 and 2 and in Tables 1 and 2.
- DOP reduced alcohol consumption and alcohol preference, preferably within the first four hours after administration.
- Table 2 Synergy between deoxpeganine po (DOP) and mecamylamine ip (Mec) in reducing the consumption of 10% aqueous ethanol solution by female AA rats.
- the administration according to the invention can take place either in the form of a single medicament with a fixed combination of both active ingredients, or else by administration in separate administration forms.
- deoxypeganine HCl can be administered orally in the form of tablets or capsules, the daily dose being 50 to 750 mg and a daily dose of 100 to 400 mg being preferred, which can be divided into any number of individual doses.
- deoxypeganm-containing transdermal therapeutic systems and oral and parenteral administration forms with delayed release, as described in DE-199 06 974 and the documents WO 00/48600 and EP-1 154 776 derived therefrom be used, usable; the preferred daily dose is 50-250 mg and is preferably given in a single dose.
- mecamylamine can be administered orally, for example in the form of the Inversin TM preparation (Targacept, Inc., USA; tablets containing 2.5 mg of racemic mecamylamine hydrochloride), the daily dose being 2.5-20 mg and a daily dose of 2.5 - 7.5 mg is preferred.
- transdermal systems or oral dosage forms with delayed release formulated according to the usual galenical methods can be used, the daily dose being 0.5-10 mg and preferably being administered in a single dose.
- deoxypeganm and mecamylamine can also be administered in the form of medicaments which contain fixed combinations of the two active compounds, which, depending on the type of administration, are designed such that the daily dose of deoxypeganine is 50 to 750 mg and that of mecamylamine is 0.5 - Can be 20 mg.
- salts is to be understood as meaning, but not exclusively, the salts of the compounds according to the invention with hydrohalic acids and with simple organic acids, such as tartaric acid (tartrates), succinic acid (succinates), maleic acid (maleates), etc.
- the treatment described above with combinations of deoxypeganm and mecamylamine can be preceded by a pretreatment which is carried out exclusively with racing ischemic mecamylamine or its individual isomers and is carried out with daily doses between 0.5 and 20 mg and between one day and five days can take.
- compositions which are used according to the present invention for the administration of a combination of 3-deoxypeganm or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives can contain one or more of the following additives:
- surfactants emulsifiers, solubilizers, wetting agents, defoamers
- a combination of 3-deoxypeganm or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives can be administered orally or parenterally.
- drugs can be produced in known dosage forms, such as tablets, coated tablets or lozenges.
- liquid or semi-liquid dosage forms are also suitable, the active ingredient being present as a solution or suspension.
- Water, aqueous media or pharmacologically acceptable oils can be used as solvents or suspending agents.
- transdermal or transmucosal dosage forms can be used particularly advantageously for the administration according to the invention of a combination of 3-deoxypeganm or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives, in particular adhesive transdermal therapeutic systems (active substance plasters).
- adhesive transdermal therapeutic systems active substance plasters
- transdermal dosage forms are very advantageous due to other properties, e.g. B. Avoiding the first pass effect or better, more even control of blood levels.
- transdermal systems a combination of 3-deoxypeganine or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives, usually have an active substance-containing, pressure-sensitive polymer matrix which is covered on the side remote from the skin by an active substance-impermeable backing layer, and the adhesive, active ingredient-releasing surface is covered with a removable protective layer before application.
- the combination of 3-deoxypeganm or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives according to the invention can be used in the therapy of harmful alcohol consumption and alcohol addiction in order to reduce the consumption of alcohol.
- the combination according to the invention of 3-deoxypeganm or one of its pharmaceutically acceptable derivatives with mecamylamine or one of its pharmaceutically acceptable derivatives can be used for the production of medicaments for the therapy of alcohol abuse and / or alcohol addiction, in particular in order to reduce the consumption of the alcohol.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200501514A EA200501514A1 (ru) | 2003-04-25 | 2004-04-16 | Сочетания действующих веществ и способы лечения злоупотребления алкоголем |
US10/554,350 US20060199866A1 (en) | 2003-04-25 | 2004-04-16 | Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse |
MXPA05011249A MXPA05011249A (es) | 2003-04-25 | 2004-04-16 | Combinaciones de desoxipeganina y mecamilamina para el tratamiento del abuso de alcohol. |
BRPI0410507-9A BRPI0410507A (pt) | 2003-04-25 | 2004-04-16 | combinação de substáncias ativas, uso de uma combinação de substáncias e processo para o tratamento do abuso do álcool e/ou da dependência de álcool |
JP2006505158A JP2006524647A (ja) | 2003-04-25 | 2004-04-16 | アルコール乱用治療のためのデオキシペガニンとメカミルアミンの組合せ |
AU2004233564A AU2004233564A1 (en) | 2003-04-25 | 2004-04-16 | Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse |
EP04727830A EP1617831A1 (de) | 2003-04-25 | 2004-04-16 | Kombination aus desoxypeganin und mecamylamin zur behandlung des alkoholmissbrauches |
CA002523331A CA2523331A1 (en) | 2003-04-25 | 2004-04-16 | Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse |
NO20054243A NO20054243L (no) | 2003-04-25 | 2005-09-13 | Kombinasjon av desoksypeganin og mecamylamin for behandling av alkoholmisbruk. ion eller et salt derav (forkortelse: NTBC). kseptabelt salt saerlig caspofunginacetat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10318714A DE10318714B4 (de) | 2003-04-25 | 2003-04-25 | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
DE10318714.6 | 2003-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004096200A1 true WO2004096200A1 (de) | 2004-11-11 |
Family
ID=33304936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/004033 WO2004096200A1 (de) | 2003-04-25 | 2004-04-16 | Kombination aus desoxypeganin und mecamylamin zur behandlung des alkoholmissbrauches |
Country Status (18)
Country | Link |
---|---|
US (1) | US20060199866A1 (de) |
EP (1) | EP1617831A1 (de) |
JP (1) | JP2006524647A (de) |
KR (1) | KR20060006946A (de) |
CN (1) | CN1771029A (de) |
AR (1) | AR044067A1 (de) |
AU (1) | AU2004233564A1 (de) |
BR (1) | BRPI0410507A (de) |
CA (1) | CA2523331A1 (de) |
CL (1) | CL2004000881A1 (de) |
DE (1) | DE10318714B4 (de) |
EA (1) | EA200501514A1 (de) |
MX (1) | MXPA05011249A (de) |
MY (1) | MY136408A (de) |
NO (1) | NO20054243L (de) |
TW (1) | TW200427452A (de) |
WO (1) | WO2004096200A1 (de) |
ZA (1) | ZA200507213B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008045641A2 (en) * | 2006-10-10 | 2008-04-17 | The University Of Chicago | Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
CN108498493A (zh) * | 2017-02-27 | 2018-09-07 | 中国人民解放军第二军医大学 | 美加明防治晕动症或眩晕症的医药用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999017803A1 (en) * | 1997-10-03 | 1999-04-15 | Cary Medical Corporation | Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
WO2000035279A1 (en) * | 1998-12-16 | 2000-06-22 | University Of South Florida | Exo-s-mecamylamine formulation and use in treatment |
US6083962A (en) * | 1986-03-17 | 2000-07-04 | Robert J. Schaap | Agonist-anatagonist combination to reduce the use of nicotine and other drugs |
WO2000048600A1 (de) * | 1999-02-19 | 2000-08-24 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
DE3843239C1 (de) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
-
2003
- 2003-04-25 DE DE10318714A patent/DE10318714B4/de not_active Expired - Fee Related
-
2004
- 2004-04-16 AU AU2004233564A patent/AU2004233564A1/en not_active Abandoned
- 2004-04-16 EP EP04727830A patent/EP1617831A1/de not_active Withdrawn
- 2004-04-16 CA CA002523331A patent/CA2523331A1/en not_active Abandoned
- 2004-04-16 US US10/554,350 patent/US20060199866A1/en not_active Abandoned
- 2004-04-16 EA EA200501514A patent/EA200501514A1/ru unknown
- 2004-04-16 CN CNA2004800094893A patent/CN1771029A/zh active Pending
- 2004-04-16 WO PCT/EP2004/004033 patent/WO2004096200A1/de not_active Application Discontinuation
- 2004-04-16 MX MXPA05011249A patent/MXPA05011249A/es not_active Application Discontinuation
- 2004-04-16 KR KR1020057020318A patent/KR20060006946A/ko not_active Application Discontinuation
- 2004-04-16 JP JP2006505158A patent/JP2006524647A/ja active Pending
- 2004-04-16 BR BRPI0410507-9A patent/BRPI0410507A/pt not_active Application Discontinuation
- 2004-04-22 MY MYPI20041476A patent/MY136408A/en unknown
- 2004-04-23 TW TW093111538A patent/TW200427452A/zh unknown
- 2004-04-23 AR ARP040101378A patent/AR044067A1/es unknown
- 2004-04-26 CL CL200400881A patent/CL2004000881A1/es unknown
-
2005
- 2005-09-08 ZA ZA200507213A patent/ZA200507213B/en unknown
- 2005-09-13 NO NO20054243A patent/NO20054243L/no not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083962A (en) * | 1986-03-17 | 2000-07-04 | Robert J. Schaap | Agonist-anatagonist combination to reduce the use of nicotine and other drugs |
WO1999017803A1 (en) * | 1997-10-03 | 1999-04-15 | Cary Medical Corporation | Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
WO2000035279A1 (en) * | 1998-12-16 | 2000-06-22 | University Of South Florida | Exo-s-mecamylamine formulation and use in treatment |
WO2000048600A1 (de) * | 1999-02-19 | 2000-08-24 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus |
Also Published As
Publication number | Publication date |
---|---|
DE10318714A1 (de) | 2004-11-18 |
US20060199866A1 (en) | 2006-09-07 |
MY136408A (en) | 2008-09-30 |
KR20060006946A (ko) | 2006-01-20 |
TW200427452A (en) | 2004-12-16 |
CN1771029A (zh) | 2006-05-10 |
JP2006524647A (ja) | 2006-11-02 |
EP1617831A1 (de) | 2006-01-25 |
DE10318714B4 (de) | 2006-03-23 |
EA200501514A1 (ru) | 2006-04-28 |
MXPA05011249A (es) | 2005-12-14 |
NO20054243L (no) | 2005-09-13 |
CA2523331A1 (en) | 2004-11-11 |
AU2004233564A1 (en) | 2004-11-11 |
CL2004000881A1 (es) | 2005-01-21 |
ZA200507213B (en) | 2006-05-31 |
BRPI0410507A (pt) | 2006-06-20 |
AR044067A1 (es) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004012403T2 (de) | Zusammensetzungen zur beeinflussung des gewichtsverlusts | |
EP1210076A2 (de) | Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid | |
EP1397138B1 (de) | WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE | |
DE60218193T2 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
DE69926804T2 (de) | Vorrichtungen zur behandlung und diagnose des restless leg syndroms | |
WO2001013902A2 (de) | Wirkstoffkombination enthaltend clonidin und pramipexol | |
DE102007018150A1 (de) | VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz | |
DE10163667B4 (de) | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression | |
DE10318714B4 (de) | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches | |
DD242749A5 (de) | Verbesserte entzuendungshemmende zusammensetzungen und verfahren | |
EP1154776B1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
DE602004008440T2 (de) | Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen | |
EP1404341B1 (de) | Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit | |
EP1667769A2 (de) | Verwendung von galanthamin und seinen derivaten zum herstellen von arzneimitteln | |
EP1383503B1 (de) | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
DE10354893B4 (de) | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen | |
DD297557A5 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
DE69816790T2 (de) | Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen | |
DE10001785A1 (de) | NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms | |
AT506159A2 (de) | Formulierung zur erhöhung der motorischen leistung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/07213 Country of ref document: ZA Ref document number: 200507213 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004727830 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 542728 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048094893 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/011249 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 171485 Country of ref document: IL Ref document number: 4811/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2523331 Country of ref document: CA Ref document number: 10554350 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057020318 Country of ref document: KR Ref document number: 2004233564 Country of ref document: AU Ref document number: 2006505158 Country of ref document: JP Ref document number: 200501514 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2004233564 Country of ref document: AU Date of ref document: 20040416 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004233564 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057020318 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004727830 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0410507 Country of ref document: BR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004727830 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10554350 Country of ref document: US |